Publications
Find coverage of the latest original articles on Lupus, focusing on those with data on therapeutic interventions and those that have clinical impact.
July 2024
Association of sustained lupus low disease activity state with improved outcomes in systemic lupus erythematosus: a multinational prospective cohort study
Lancet Rheumatol 2024:S2665-9913(24)00121-8 DOI 10.1016/S2665-9913(24)00121-8 Epub ahead of print
This study by Golder, et al. showed a significant protective association of lupus low disease activity state (LLDAS) and remission against damage accrual and flare. The authors also found a threshold of 3 months sustained LLDAS or remission, and that 3 months of sustained LLDAS are attainable in the setting of a 6–12-month clinical trial.
Keywords:
March 2024
Lupus low disease activity state and organ damage in relation to quality of life in systemic lupus erythematosus: A cohort study with up to 11 years of follow-up
Rheumatology 2024 DOI 10.1093/rheumatology/keae120 Epub ahead of print
Patients with a lupus low disease activity state (LLDAS) irrespective of organ damage were significantly more likely to have favourable health-related quality of life, pain, fatigue, and overall health experience.
February 2023
Relationship Between the EULAR/ACR Classification Criteria and Organ Damage in Systemic Lupus Erythematosus
Lupus. 2023. doi: 10.1177/09612033231153791
Ambispective cohort study concludes that, in addition to disease classification, the EULAR/ACR SLE criteria may have value in predicting prognosis.
Keywords:
November 2022
Lupus Low Disease Activity State and Remission and Risk of Mortality in Patients with Systemic Lupus Erythematosus: A Prospective, Multinational, Longitudinal Cohort Study
Lancet Rheumatol. 2022. Epub ahead of print. doi: 10.1016/S2665-9913(22)00304-6
Lupus low disease activity state (LLDAS) significantly reduced the risk of mortality in patients with SLE.
May 2022
Impact of belimumab on organ damage in systemic lupus erythematosus
Arthritis Care Res (Hoboken). 2022 Epub ahead of print doi: 10.1002/acr.24901
Review of clinical trial and real-world data on the effects of belimumab on organ damage in adult patients with SLE shows that belimumab reduces key drivers of organ damage, decreases organ damage progression and, in those with lupus nephritis (LN), decreases renal-related events.
Keywords:
January 2022
2019-EULAR/ACR Classification Criteria Domains at Diagnosis: Predictive Factors of Long-Term Damage In Systemic Lupus Erythematosus
Clin Rheumatol. 2021. Epub ahead of print
Single-centre, retrospective analysis identifying that specific domains in the 2019-EULAR/ACR criteria at diagnosis are associated with long-term organ-specific damage, particularly renal and neuropsychiatric harm.
October 2021
Long-term Organ Damage Accrual and Safety in Patients with SLE Treated with Belimumab Plus Standard of Care
Lupus 2016;25:699–709
Both active disease and medication toxicity can result in the accrual of long-term organ damage in SLE.